Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

PET-CT scans could sharpen radiation targeting for liver tumors

NCT ID NCT02088775

Knowledge-focused Sponsor: Fox Chase Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study investigates whether PET-CT scans can accurately measure the radiation dose delivered by radioactive spheres during a liver cancer treatment called radioembolization. Researchers will compare scans taken before and after the procedure in patients with liver tumors. The goal is to see if this imaging method can help doctors plan more effective and safer radiation doses in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radioactive spheres (SIR-Spheres or TheraSphere)
What this could lead to
If successful, this approach could help doctors plan more precise radiation doses for liver cancer, potentially improving tumor control while reducing side effects.
What could go wrong
This is an observational registry study, not a treatment trial. It may not lead to changes in practice, and results may vary by tumor type or sphere type.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

44 people

The number who actually took part.

Started

Feb 2014

Finished

Jul 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients must have liver-dominant or liver-only metastatic disease from any primary histology; patients with primary hepatocellular or biliary cancer are also eligible * Patients must be clinical candidates for radioembolization with either SIR-spheres or TheraSphere due to metastatic or primary malignancies of the liver * Women of child bearing potential must have a negative serum pregnancy test no more than 72 hours prior to registration * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2 * Ability to understand and willingness to sign a written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of medical information * Complete blood count (CBC) and chemistry panel (CMP) no greater than 4 weeks prior to visit 1 * Diagnostic imaging of the abdomen utilizing either CT with contrast, magnetic resonance imaging (MRI), or PET/CT no greater than 4 weeks prior to visit 1 Exclusion Criteria: * Patients not undergoing radioembolization to the liver * Women of childbearing potential (WOCBP) and men who refuse to comply with appropriate contraception * Women who are either pregnant or breast feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adult primary hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adult hepatocellular carcinoma bile duct neoplasm biliary tract cancer cancer extrahepatic bile duct carcinoma hepatocellular carcinoma malignant tumor of extrahepatic bile duct

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adult primary hepatocellular carcinoma Advanced adult primary liver cancer Metastatic extrahepatic bile duct cancer Recurrent adult primary liver cancer Recurrent extrahepatic bile duct cancer Stage D adult primary liver cancer (BCLC) Unspecified adult solid tumor, protocol specific

Contacts and locations

Locations

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.